| abstract |
Disclosed are compounds of formula I formula I and it finds utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-IR), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of c-FMS, c-KIT, or other mammalian diseases mediated by PDGFR kinase. |